USANA Health Sciences (NYSE:USNA) Issues Earnings Results, Misses Expectations By $0.50 EPS

USANA Health Sciences (NYSE:USNA) issued its earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.50), FiscalAI reports. The company had revenue of $223.27 million during the quarter, compared to the consensus estimate of $235.00 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.

USANA Health Sciences Price Performance

Shares of NYSE:USNA traded up $0.05 on Tuesday, hitting $22.89. The company’s stock had a trading volume of 103,018 shares, compared to its average volume of 119,668. The company has a 50-day simple moving average of $20.53 and a 200 day simple moving average of $19.77. USANA Health Sciences has a 1 year low of $16.60 and a 1 year high of $32.32. The company has a market capitalization of $422.53 million, a PE ratio of 48.70, a PEG ratio of 0.87 and a beta of 0.73.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on USNA. Wall Street Zen upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, June 20th. Zacks Research lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce”.

Insiders Place Their Bets

In related news, insider Brent Neidig sold 5,002 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $19.45, for a total value of $97,288.90. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO G Doug Iiekking sold 5,360 shares of USANA Health Sciences stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $18.75, for a total transaction of $100,500.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 17,660 shares of company stock worth $336,579 over the last three months. Company insiders own 0.82% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in USNA. Russell Investments Group Ltd. boosted its holdings in shares of USANA Health Sciences by 4.6% in the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock worth $244,000 after purchasing an additional 542 shares in the last quarter. First Trust Advisors LP purchased a new position in shares of USANA Health Sciences during the 4th quarter valued at about $246,000. Wells Fargo & Company MN lifted its position in USANA Health Sciences by 37.9% in the 4th quarter. Wells Fargo & Company MN now owns 13,311 shares of the company’s stock worth $261,000 after buying an additional 3,655 shares during the last quarter. Brooklyn Investment Group bought a new stake in USANA Health Sciences in the 4th quarter worth approximately $263,000. Finally, Intech Investment Management LLC boosted its stake in USANA Health Sciences by 13.5% in the third quarter. Intech Investment Management LLC now owns 7,722 shares of the company’s stock worth $213,000 after buying an additional 918 shares in the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.